Cargando…

Opposing Roles of Membrane and Soluble Forms of the Receptor for Advanced Glycation End Products in Primary Respiratory Syncytial Virus Infection

Respiratory syncytial virus (RSV), a common respiratory pathogen in infants and the older population, causes pulmonary inflammation and airway occlusion that leads to impairment of lung function. Here, we have established a role for receptor for advanced glycation end products (RAGE) in RSV infectio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Allison L., Sims, Gary P., Brewah, Yambasu A., Rebelatto, Marlon C., Kearley, Jennifer, Benjamin, Ebony, Keller, Ashley E., Brohawn, Philip, Herbst, Ronald, Coyle, Anthony J., Humbles, Alison A., Kolbeck, Roland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2012
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308901/ https://www.ncbi.nlm.nih.gov/pubmed/22262795 http://dx.doi.org/10.1093/infdis/jir826

Ejemplares similares

RAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein function
por: Tian, Jane, et al.
Publicado: (2013)

S100A9 Induced Inflammatory Responses Are Mediated by Distinct Damage Associated Molecular Patterns (DAMP) Receptors In Vitro and In Vivo
por: Chen, Bo, et al.
Publicado: (2015)

RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA
por: Sirois, Cherilyn M., et al.
Publicado: (2013)

RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA
por: Sirois, Cherilyn M., et al.
Publicado: (2014)

Strain-specific requirement for eosinophils in the recruitment of T cells to the lung during the development of allergic asthma
por: Walsh, Elizabeth Rose, et al.
Publicado: (2008)

Transmission of Respiratory Syncytial Virus Infection Within Families
por: Heikkinen, Terho, et al.
Publicado: (2014)

Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue
por: Jogdand, Prajakta, et al.
Publicado: (2020)

IL-33 Mediates Lung Inflammation by the IL-6-Type Cytokine Oncostatin M
por: Botelho, Fernando, et al.
Publicado: (2020)

Epidemiology and Characteristics of Respiratory Syncytial Virus Pneumonia in Critically Ill Adults
por: Kim, Taeeun, et al.
Publicado: (2023)

Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012
por: Pastula, Susan T., et al.
Publicado: (2017)

Recurrent Respiratory Syncytial Virus Infection in a CD14-Deficient Patient
por: Besteman, Sjanna B, et al.
Publicado: (2022)

Estimation of the Number of Respiratory Syncytial Virus–Associated Hospitalizations in Adults in the European Union
por: Osei-Yeboah, Richard, et al.
Publicado: (2023)

Advanced Glycation End Products Associated With Cardiometabolic Biomarkers in Treated Human Immunodeficiency Virus Infection
por: El Kamari, Vanessa, et al.
Publicado: (2021)

Clinical Burden of Respiratory Syncytial Virus in Hospitalized Children Aged ≤5 Years (INSPIRE Study)
por: Hartmann, Katrin, et al.
Publicado: (2022)

Pediatric Respiratory Syncytial Virus Diagnostic Testing Performance: A Systematic Review and Meta-analysis
por: Onwuchekwa, Chukwuemeka, et al.
Publicado: (2023)

Severity of Respiratory Syncytial Virus Lower Respiratory Tract Infection With Viral Coinfection in HIV-Uninfected Children
por: Mazur, Natalie I., et al.
Publicado: (2017)

Transmission of Respiratory Syncytial Virus Among Children Under 5 Years in Households of Rural Communities, the Philippines
por: Otomaru, Hirono, et al.
Publicado: (2019)

Impact of the Coronavirus Disease 2019 Pandemic on the Clinical Features of Pediatric Respiratory Syncytial Virus Infection in Japan
por: Ozeki, Shoko, et al.
Publicado: (2022)

Antibody Correlates of Protection From Severe Respiratory Syncytial Virus Disease in a Vaccine Efficacy Trial
por: Fong, Youyi, et al.
Publicado: (2023)

Respiratory Syncytial Virus–Related Complications and Healthcare Costs Among a Medicare-Insured Population in the United States
por: DeMartino, Jessica K, et al.
Publicado: (2023)

Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years
por: Del Riccio, Marco, et al.
Publicado: (2023)

Respiratory Syncytial Virus Incidence and Severity in a Community-Based Prospective Cohort of Children Aged 0–14 Years
por: Smith, Matthew, et al.
Publicado: (2022)

Pneumococcal Conjugate Vaccines Are Protective Against Respiratory Syncytial Virus Hospitalizations in Infants: A Population-Based Observational Study
por: Le, Huong, et al.
Publicado: (2023)

Viral Genetic Determinants of Prolonged Respiratory Syncytial Virus Infection Among Infants in a Healthy Term Birth Cohort
por: Lawless, Dylan, et al.
Publicado: (2022)

Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine
por: Jordan, Elke, et al.
Publicado: (2023)

Age-Dependent Risk of Respiratory Syncytial Virus Infection: A Systematic Review and Hazard Modeling From Serological Data
por: Nakajo, K, et al.
Publicado: (2023)

Incidence of Medically Attended Respiratory Syncytial Virus and Influenza Illnesses in Children 6–59 Months Old During Four Seasons
por: Simpson, Melissa D., et al.
Publicado: (2016)

Factors Predicting Secondary Respiratory Morbidity Following Early-Life Respiratory Syncytial Virus Infections: Population-Based Cohort Study
por: Sarna, Mohinder, et al.
Publicado: (2023)

Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis
por: Onwuchekwa, Chukwuemeka, et al.
Publicado: (2023)

Systematic Literature Review of Risk Factors for Poor Outcomes Among Adults With Respiratory Syncytial Virus Infection in High-Income Countries
por: Njue, Annete, et al.
Publicado: (2023)

Leveraging Influenza Virus Surveillance From 2012 to 2015 to Characterize the Burden of Respiratory Syncytial Virus Disease in Canadian Adults ≥50 Years of Age Hospitalized With Acute Respiratory Illness
por: ElSherif, May, et al.
Publicado: (2023)

A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults
por: Baber, James, et al.
Publicado: (2022)

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial
por: Bebia, Zourab, et al.
Publicado: (2023)

Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32–35 Weeks Gestational Age
por: Franklin, Jeremy A., et al.
Publicado: (2016)

Retinoic Acid–Inducible Gene I Activation Inhibits Human Respiratory Syncytial Virus Replication in Mammalian Cells and in Mouse and Ferret Models of Infection
por: Schwab, Lara S U, et al.
Publicado: (2022)

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
por: Sadoff, Jerald, et al.
Publicado: (2021)

Respiratory Syncytial Virus Disease Burden in Community-Dwelling and Long-Term Care Facility Older Adults in Europe and the United States: A Prospective Study
por: Narejos Pérez, Sílvia, et al.
Publicado: (2023)

Influenza A and Respiratory Syncytial Virus Trigger a Cellular Response That Blocks Severe Acute Respiratory Syndrome Virus 2 Infection in the Respiratory Tract
por: Dee, Kieran, et al.
Publicado: (2022)

Soluble CD163 Identifies Those at Risk for Increased Hepatic Inflammation & Fibrosis
por: Sherman, Kenneth E, et al.
Publicado: (2021)

Incidence of Respiratory Syncytial Virus Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across Diverse Global Settings( )
por: Langley, Joanne M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dkeu44vc302udeel711l8omir5